Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$9.36
$9.36
$9.10
$12.00
$37.49M0.53600 shsN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
$5.47
$5.47
$5.47
$352.00
$127.45M2.46279 shsN/A
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
$0.00
$0.50
$1.86
$105.76MN/A71,826 shs50,100 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00%0.00%0.00%0.00%+2.86%
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
0.00%0.00%0.00%0.00%0.00%
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$9.36
$9.36
$9.10
$12.00
$37.49M0.53600 shsN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
$5.47
$5.47
$5.47
$352.00
$127.45M2.46279 shsN/A
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
$0.00
$0.50
$1.86
$105.76MN/A71,826 shs50,100 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00%0.00%0.00%0.00%+2.86%
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
0.00%0.00%0.00%0.00%0.00%
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00
N/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
0.00
N/AN/AN/A
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$6.82M24.50N/AN/A$0.21 per share44.57
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
$36.55M3.49N/AN/A($67.63) per share-0.08
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
-$17.63MN/A0.00N/AN/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
-$150.73MN/A0.00N/A-894.02%-3,350.55%-67.76%N/A
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/AN/AN/AN/AN/A
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/A
0.95
0.71
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
2217.85 millionN/ANot Optionable
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
5023.31 millionN/ANot Optionable
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/A113.72 millionN/ANot Optionable

Recent News About These Companies

Valeo Pharma Inc. (VPHIF)
About Tribute.ca
Ron Canada Biography & Movies
Newron Pharmaceuticals stock logo

Newron Pharmaceuticals OTCMKTS:NWPHF

$9.36 0.00 (0.00%)
As of 09/5/2025

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

ProMetic Life Sciences stock logo

ProMetic Life Sciences OTCMKTS:PFSCF

$5.47 0.00 (0.00%)
As of 11/18/2019

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Tribute Pharmaceuticals Canada stock logo

Tribute Pharmaceuticals Canada OTCMKTS:TBUFF

Tribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.